

Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ

Ref: FOI-032026-0002306

Date: 20.04.2026

Address / Email:

Dear

Request Under Freedom of Information Act 2000

Thank you for requesting information under the Freedom of Information Act 2000, please see response below.

Q1. How many patients were treated in the last 3 months with any systemic anti-cancer therapies for Gastric cancer or cancer of the Gastro-Oesophageal Junction? **17**

Q2. How many patients were treated in the past 3 months for gastric cancer (any stage) with:

- CAPOX (Capecitabine with Oxaliplatin) **2**
- FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) **2**
- Lonsurf (Trifluridine - tipiracil) **0**
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) **0**
- Pembrolizumab (any formulation) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) **4**
- Pembrolizumab (395 mg or 790mg solution for injection only) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) **0**
- Zolbetuximab (Vyloy) **0**
- Any other systemic anti-cancer therapy **4**
- Palliative care only - **Only active treatment recorded**

Q3. How many patients were treated in the past 3 months for cancer of the gastro-oesophageal junction (any stage) with:

- CAPOX (Capecitabine with Oxaliplatin) **1**
- FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) **2**
- Lonsurf (Trifluridine - tipiracil) **0**
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) **0**
- Pembrolizumab (any formulation) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) **1**
- Pembrolizumab (395 mg or 790mg solution for injection only) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) **0**
- Zolbetuximab (Vyloy) **0**
- Any other systemic anti-cancer therapy **7**

- Palliative care only - **Only active treatment recorded**

Q4. If you have been unable to answer any of the above questions because you do not treat Gastric or Gastro-Oesophageal Cancer, to which site do you refer patients that require either treatment? – **N/A**

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager
Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ
Email: dgft.dpo@nhs.net

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
Tel: 0303 123 1113
www.ico.org.uk

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team
The Dudley Group NHS Foundation Trust